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Background: Cystic Fibrosis (CF) is a genetic disease with equal prevalence across sexes. However, women present
worse lung function with faster function decline, earlier onset of bacterial colonization, more frequent pulmonary
exacerbations (PE), greater bronchial hyper-responsiveness, and higher mortality rates after puberty than men. The
etiology of this gender disparity remains elusive but female hormones have been implicated in several studies.
Case presentation: A 20-year-old female with CF with severe recurrent PE, always related to the menstrual cycle
since menarche, combined with lung function decline requiring multiple courses of intravenous antibiotics. We
report the cessation of PE and recovery of pulmonary function following the insertion of a subcutaneous implant
with 68 mg of etonogestrel (Implanon®, Organon Española S.A. Laboratories, Madrid, Spain).
Conclusion: Our case report supports the key role of female hormones in the development of PE and in the
decline of lung function in a woman with CF. When appropriate, hormonal manipulation through contraceptive
methods should be considered as potential treatment.
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Gender differences in the presentation of Cystic Fibrosis
(CF) after puberty have been well described in the litera-
ture including a shorter median life expectancy by close
to 3 years observed in women compared to men [1-4].
The etiology of this gender disparity remains unclear but
several factors such nutritional status, CF-related dia-
betes, lung function (LF), airway microbiota, pulmonary
exacerbations (PE), and sex hormones have been associ-
ated with it in previous studies [5,6].
Estrogens (E) are involved in mucus secretion, lung
development, expression of inflammation factors, and the
risk of acquiring Pseudomonas aeruginosa (P. aeruginosa)
including its conversion to the mucoid phenotype. In
addition, E are also linked to increased activity of the so-
dium channel and Na+-K−ATPase, a decrease in the chlor-
ide secretion mediated by the calcium channel, reduced* Correspondence: adelaida.lamas@salud.madrid.org
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unless otherwise stated.airway surface liquid (ASL) height, and a modification
in the activity of the cystic fibrosis transmembrane con-
ductance regulator (CFTR) [7-17]. Finally, the expres-
sion of progesterone (P) receptors in the cilia of airway
epithelium is regulated by sex hormones. P decreases
cilia beat frequency in human airway epithelial cells by
approximately 40% and this reduced cilia beat frequency
may, in turn, contribute to impaired mucociliary clearance
(MCC) [18].
These findings suggest an association between the
changes in female hormones related to patient’s men-
strual cycle with the documented gender disparity in
CF-related morbidity and mortality [10,19]. Based on
Irish register data, Chotirmall and colleagues reported
that female CF patients on the oral contraceptive pill
(OCP) required fewer antibiotic courses and had a
lower PE rate than their counterparts not on OCP [8].
Sutton et al. [4] studied the effects of puberty on CF-
related PE in women versus men by performing a cohort
study using the United States Cystic Fibrosis Foundation
Patient Registry. Post-puberty, the number of PE per year
in males was 0.24 lower than in females. Below we presentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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with etonogestrel (Implanon®) to reduce PE frequency and
improve LF in a woman with CF.
Case presentation
The patient was a 20-year-old female with CF, genotype
R334W/Q890X and pancreatic sufficiency, diagnosed as
a 3 month-old due to respiratory symptoms. Since diagno-
sis, the patient had had several PE caused by β-lactamase
producer methicillin-susceptible Staphylococcus aureus
(S. aureus). At the age of 5, she experienced the first of
many acute pancreatitis (AP) episodes secondary to sev-
eral oral medications, including antibiotics. These epi-
sodes, associated with continuous PE, led to the insertion
of a port-a-cath. Non mucoid P. aeruginosa isolations
grew in five samples from April 2000 to September 2009
and three samples of Stenotrophomonas maltophilia were
also collected, once in 2005 and twice in 2010. The pa-
tient was treated with intermittent aerosolized antibiotics
(tobramycin and colistin) following the Spanish Protocol
for eradication of P. aeruginosa, and was on azythromy-
cin (500 mg, three times a week) from February 2007 to
July 2009 [20]. Sputa acid-fast bacilli smears and cultures
for mycobacterium isolates were consistently negative.
From the onset of menarche at the age of 14, PE had
followed the same pattern. Four days before the men-
strual period, she would start experiencing increased
cough and purulent sputum production, develop daily
fever (>38°C), exertional dyspnea, and anorexia. In
February 2007, due to frequent PE and rapid LF decline,
she was started on aerosolized ampicillin (Gobemicina®,
Normon Laboratories, Madrid, Spain) every 12 hours. As
previously reported [21], the response to this treatment
was excellent for a year. On February 2008 she again suf-
fered severe and frequent PE, even while on aerosolized
ampicillin, and always related to menstrual cycle as de-
scribed above. We then introduced an OCP with 3 mg
of drospirenona and 30 mcg of etinilestradiol (Yasmin
Diario®, Schering España S.A. Laboratories, Madrid, Spain)
with initial good response and no PE for 7 months. On
September 2008, the same pattern of PE described above
re-started requiring five courses of intravenous (IV) antibi-
otics. From March through May of 2009, the patient was
administered an OCP with 2.0 mg of ciproterone acetate
and 0.035 mg of etinilestradiol (Diane 35®, Schering
España S.A. Laboratories, Madrid, Spain). The lack of
response called for four courses of IV antibiotics. In
total, from February 2008 until May 2009 she required
20 weeks of IV antibiotics (ceftazidime, linezolid, imipe-
nem, trimethoprim-sulfamethoxazole, or a combination
of these; Figure 1). We observed a dramatic loss of LF as
follows (Figure 1): forced expired volume in 1 second
(FEV1) decreased from 2.33 L to 1.31 L (77% to 42% of
FEV1 predicted) and forced vital capacity (FVC) decreasedfrom 2.71 L to 1.49 L (79% to 42% of FVC predicted).
In addition, she had five AP episodes. In May 2009, after
discussing the case with the Department of Gynaecology,
a subcutaneous implant with 68 mg of etonogestrel
(Implanon®, Organon Española S.A. Laboratories, Madrid,
Spain) was inserted in the inner side of her left arm. Estra-
diol levels had not been measured in this patient. Since
then the patient had no PE episodes for two years, she did
not require any oral or IV antibiotics, and her LF stabilized
around 1.61 L for FEV1 (48% of FEV1 predicted) and 2.16
for FVC (57% of FVC predicted). In addition, the treat-
ment resulted in a weight gain of 3 Kg (from 50 kg [10th
percentile] to 53 kg [25th-50th percentile]). Further,
no side effects were observed during this period, the
pattern of S. aureus colonization did not change, and no
selection of resistant microorganisms appeared except a
unique isolation of non-mucoid P. aeruginosa, previously
reported, four months after the insertion of the subcutane-
ous implant. From September 2009 through September
2010, we introduced aerosolized tobramycin (TOBI®,
Novartis Laboratories) in on-off cycles following the
Spanish Protocol for eradication of P. aeruginosa. In
July 2011, the patient had a severe PE episode requiring
treatment with IV antibiotic. At this point, the subcuta-
neous implant was replaced for another one. The patient
has been PE episode-free since December 2012.
Discussion
CF is a genetic disease with the same prevalence in both
men and women. However, women experience worse LF,
early onset bacterial colonisations, and lower survival ex-
pectancy than men [1-3,22]. E levels are involved in
mucus secretion, lung development, expression of in-
flammation factors, risk for P. aeruginosa colonization
and its further conversion to mucoid phenotype, modifi-
cation of the activity of the CFTR, and alterations of
MCC and ion transport in the ASL [10,15,19,23]. Add-
itionally, P decreases cilia beat frequency in airway epi-
thelial cells [18]. These effects have a negative impact on
the MCC of the ASL which may explain, to an import-
ant extent, the lower survival in women with CF com-
pared to their male counterparts.
All these mechanisms could have influenced the pres-
entation of PE in our patient during the luteal phase
when E and P levels are high. The OCP administered
(Yasmin Diario® o Diane 35 Diario®) has a negative feed-
back mechanism on hypophysis hormones lowering
endogenous E’s levels throughout the menstrual cycle,
including the pre-ovulation peak. The subcutaneous im-
plant of etonogestrel (Implanon®, Organon Española S.A.
Laboratories, Madrid, Spain) has a slow and sustained
release of a P derivate which inhibits endogenous pro-
gesterone levels throughout the menstrual cycle, includ-
ing the luteal phase.
Figure 1 Respiratory function and intravenous-antibiotic use before and after insertion of first and seconf subcutaneous
implant with etonogestrel (Implanon®). ⬇: intravenous antibic; FVC: forced vital capacity; FEV1: forced expired volumen in first second;
(1): trimethoprim-sulfamethoxazole; (2) trimethoprim-sulfamethoxazole and linezolid; (3): linezolid; (4): trimethoprim-sulfamthoxazole and
ceftazidimel; (5): Imipenem.
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tory we speculate that both the year-long effectiveness of
the aerosolized ampicillin treatment and the 7-month ef-
fectiveness of the treatment with the first OCP (Yasmin
Diario®) may be explained by the patient’s young age.
The first two years after the onset of menarche are char-
acterized by anovulatoy cycles which cause irregular E
and P patterns during the menstrual cycle. After these
two years, the patient probably started experiencing
regular ovulatory cycles which would have normalized
her E and P levels across the normal menstrual cycle. The
OCP prescribed (Yasmin Diario® and Diane 35 Diario®)
only contain E, thus, they could not be effective in this
particular case because our patient had the PE always dur-
ing the luteal phase, rather than the preovulatory, or im-
mediately before the menstrual phase of the cycle when
the E are high. We think the effectiveness of the implant,
inserted around two years and a half after menarche, was
secondary to the reduction of E and P levels caused by the
administration of exogenous P throughout the entire men-
strual cycle, including the luteal phase, while withholding
administration of exogenous E.
The efficacy of ovulatory inhibition with this type
of implant varies from woman to woman across time,
diminishing by 10% to up to 50% between year 2 and 5
after insertion. In our case, a substantial loss of efficacy
could explain the patient’s new acute PE episode after
the first two years post-insertion and the disappearance
of clinical symptoms again after the insertion of a new
implant.
The genotype of this patient (R334W, class IV muta-
tion, and Q890X, class I mutation) is uncommon and, inthis case, associated with a severe expression of the dis-
ease with pancreatic sufficiency, numerous episodes of
acute pancreatitis, and severe pulmonary disease with
frequent PE. Sutton et al. [4] analyzed the United States
CF Foundation Patient Registry for a retrospective study
of LF decline and rate of PE changes in CF before and
after puberty. They concluded that whereas males had
lower rate of PE than females, there was no association
between annual frequency of PE and race, pancreatic in-
sufficiency, or genotype. Further research is necessary to
shed light on the relationship between CF genotype and
the effect of female hormones on morbidity/mortality in
women.
The effect of female hormones on women with CF is a
complex issue given that women have different PE re-
currence patterns according to the different phases of
the menstrual cycle. Thus, studying the history of PE
pattern is essential in order to prescribe one contraceptive
method over another (with exogenous E, P, or a combin-
ation of both) according to the expression of clinical symp-
toms of each patient.
Conclusion
Pulmonary epithelium is a target for female hormones,
including E and P. Their effects on lung function, in-
flammation, and immune responses may impair MCC
and are likely to partially explain the increase in PE fre-
quency observed in women with CF. The case presented
here underlines the likely contribution of female hormones
to the sex differential in morbidity/mortality in patients
with CF. This case supports hormonal manipulation as a
potential highly effective therapy for women with CF.
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